HAEGARDA (C1 esterase inhibitor)
C1 ESTERASE INHIBITORS (PROPHYLAXIS) · PREVENTION OF ANGIOEDEMA ATTACKS IN PATIENT WITH HEREDITARY ANGIOEDEMA
CSL Behring
Drug class
C1 Esterase Inhibitors (Prophylaxis)
C1 esterase inhibitors for prophylaxis comprise a therapeutic class of plasma-derived protein replacement therapies indicated for routine, long-term prevention of recurrent angioedema attacks in patients with hereditary angioedema. Read more about C1 Esterase Inhibitors (Prophylaxis)
3 drugs in this class 3 manufacturers
Drugs in C1 Esterase Inhibitors (Prophylaxis)
CINRYZE (C1 esterase inhibitor)
C1 ESTERASE INHIBITORS (PROPHYLAXIS) · PREVENTION OF ANGIOEDEMA ATTACKS IN PATIENT WITH HEREDITARY ANGIOEDEMA
MILLENNIUM PHAR
CINRYZE (C1 esterase inhibitor)
C1 ESTERASE INHIBITORS (PROPHYLAXIS) · PREVENTION OF ANGIOEDEMA ATTACKS IN PATIENT WITH HEREDITARY ANGIOEDEMA
Takeda Pharmaceuticals America
Filter & compare in the drug finder →
Opens the drug finder with C1 Esterase Inhibitors (Prophylaxis) preselected. Add indication or manufacturer filters there.
C1 esterase inhibitors for prophylaxis comprise a therapeutic class of plasma-derived protein replacement therapies indicated for routine, long-term prevention of recurrent angioedema attacks in patients with hereditary angioedema.
Hereditary angioedema is an autosomal dominant disorder characterized by a quantitative deficiency or functional dysfunction of endogenous C1 esterase inhibitor.
These replacement agents function by replenishing functional levels of the serpin C1 inhibitor, thereby restoring physiological regulation over the complement, contact, and fibrinolytic cascades.
By inhibiting key serine proteases such as plasma kallikrein and activated factor XII, they suppress the excessive generation of bradykinin, effectively preventing bradykinin-mediated vasodilation, increased vascular permeability, and subcutaneous or submucosal swelling attacks.
-
nih.gov
C1 esterase inhibitors for prophylaxis comprise a therapeutic class of plasma-derived protein replacement therapies indicated for routine, long-term prevention of recurrent angioedema attacks in patients with hereditary angioedema
-
nih.gov
C1 esterase inhibitors for prophylaxis comprise a therapeutic class of plasma-derived protein replacement therapies indicated for routine, long-term prevention of recurrent angioedema attacks in patients with hereditary angioedema
-
nih.gov
C1 esterase inhibitors for prophylaxis comprise a therapeutic class of plasma-derived protein replacement therapies indicated for routine, long-term prevention of recurrent angioedema attacks in patients with hereditary angioedema These replacement agents function by replenishing functional levels of the serpin C1 inhibitor, thereby restoring physiological regulation over the complement, contact, and fibrinolytic cascades By inhibiting key serine proteases such as plasma kallikrein and activated...
-
fda.gov
Hereditary angioedema is an autosomal dominant disorder characterized by a quantitative deficiency or functional dysfunction of endogenous C1 esterase inhibitor
-
nih.gov
Hereditary angioedema is an autosomal dominant disorder characterized by a quantitative deficiency or functional dysfunction of endogenous C1 esterase inhibitor These replacement agents function by replenishing functional levels of the serpin C1 inhibitor, thereby restoring physiological regulation over the complement, contact, and fibrinolytic cascades By inhibiting key serine proteases such as plasma kallikrein and activated factor XII, they suppress the excessive generation of bradykinin, eff...
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.